Aberdeen Group plc Has $516.31 Million Stock Position in AbbVie Inc. $ABBV

Aberdeen Group plc grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,259,641 shares of the company’s stock after acquiring an additional 4,225 shares during the period. AbbVie comprises 0.8% of Aberdeen Group plc’s holdings, making the stock its 14th largest holding. Aberdeen Group plc owned about 0.13% of AbbVie worth $516,305,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ABBV. Ellenbecker Investment Group grew its position in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA raised its position in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC raised its position in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC lifted its stake in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC boosted its holdings in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV opened at $208.79 on Friday. The stock has a 50-day moving average of $221.79 and a 200-day moving average of $224.48. The company has a market cap of $369.17 billion, a PE ratio of 88.47, a P/E/G ratio of 0.75 and a beta of 0.38. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Piper Sandler raised their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Evercore lowered their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.